@article{JTD29499,
author = {Yasuhiro Kato and Yukio Hosomi and Kageaki Watanabe and Makiko Yomota and Shoko Kawai and Yusuke Okuma and Kaoru Kubota and Masahiro Seike and Akihiko Gemma and Tatsuru Okamura},
title = {Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {6},
year = {2019},
keywords = {},
abstract = {Background: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared with the clinical trials, in real-world clinical practice, osimertinib must be administered to older patients and those with poor Eastern Cooperative Oncology Group performance status (ECOG-PS). Therefore, we investigated the association between osimertinib efficacy/safety and PS score, age, and other clinical features in patients with T790M-positive NSCLC.
Methods: We reviewed all patients with T790M-positive NSCLC and acquired resistance to initial EGFR-TKIs who were administered osimertinib between March 2016 and January 2018 at the Tokyo Metropolitan Cancer and Infectious Diseases Center in Komagome Hospital, Japan.
Results: In total, 31 patients, including 8 young (},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/29499}
}